Sarah A Weicker1, Kanna Hayashi2, Cameron Grant1, M-J Milloy3, Evan Wood3, Thomas Kerr4. 1. British Columbia Centre on Substance Use, British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada. 2. British Columbia Centre on Substance Use, British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada; Faculty of Health Sciences, Simon Fraser University, Blusson Hall, 8888 University Drive, Burnaby, BC, V5A 1S6, Canada. 3. British Columbia Centre on Substance Use, British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada; Department of Medicine, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada. 4. British Columbia Centre on Substance Use, British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada; Department of Medicine, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada. Electronic address: bccsu-tk@bccsu.ubc.ca.
Abstract
OBJECTIVES: Opioid agonist therapy is the cornerstone of treatment of opioid use disorder. In Canada, buprenorphine/naloxone has recently been adopted as the first line agonist therapy given its comparable effectiveness to methadone and superior safety profile. This study examines factors associated with willingness to take buprenorphine/naloxone among opioid users. METHODS: Data were derived from two prospective cohorts of high-risk individuals who use drugs in Vancouver, Canada. Multivariable logistic regression analyses were used to determine factors associated with willingness to use buprenorphine/naloxone among people who use opioids and were not currently accessing this treatment option. Participants who were unwilling to use buprenorphine/naloxone were invited to provide reason(s) and their responses were examined in a sub-analysis. RESULTS: Between December 2014 and May 2018, 1103 participants were interviewed. Overall, 194 (17.6%) respondents indicated that they would be willing to take buprenorphine/naloxone. Variables independently associated with willingness were previous buprenorphine/naloxone treatment (adjusted odds ratio [AOR] = 2.04), having ever used methadone treatment (AOR = 1.87), and age (AOR = 0.98, per year older) (all p < 0.05). Satisfaction with current agonist therapy (25.4%), not knowing what buprenorphine/naloxone is (25.1%), and wanting more information about buprenorphine/naloxone (15.1%) were the most commonly cited reasons for unwillingness. A low rate of willingness to use buprenorphine/naloxone (15.1%) was also observed among the sub-set of participants not using methadone. CONCLUSIONS: While an overall low level of willingness to take buprenorphine/naloxone was observed, this appeared to be largely driven by satisfaction with other agonists and a low prevalence of community knowledge about buprenorphine/naloxone.
OBJECTIVES: Opioid agonist therapy is the cornerstone of treatment of opioid use disorder. In Canada, buprenorphine/naloxone has recently been adopted as the first line agonist therapy given its comparable effectiveness to methadone and superior safety profile. This study examines factors associated with willingness to take buprenorphine/naloxone among opioid users. METHODS: Data were derived from two prospective cohorts of high-risk individuals who use drugs in Vancouver, Canada. Multivariable logistic regression analyses were used to determine factors associated with willingness to use buprenorphine/naloxone among people who use opioids and were not currently accessing this treatment option. Participants who were unwilling to use buprenorphine/naloxone were invited to provide reason(s) and their responses were examined in a sub-analysis. RESULTS: Between December 2014 and May 2018, 1103 participants were interviewed. Overall, 194 (17.6%) respondents indicated that they would be willing to take buprenorphine/naloxone. Variables independently associated with willingness were previous buprenorphine/naloxone treatment (adjusted odds ratio [AOR] = 2.04), having ever used methadone treatment (AOR = 1.87), and age (AOR = 0.98, per year older) (all p < 0.05). Satisfaction with current agonist therapy (25.4%), not knowing what buprenorphine/naloxone is (25.1%), and wanting more information about buprenorphine/naloxone (15.1%) were the most commonly cited reasons for unwillingness. A low rate of willingness to use buprenorphine/naloxone (15.1%) was also observed among the sub-set of participants not using methadone. CONCLUSIONS: While an overall low level of willingness to take buprenorphine/naloxone was observed, this appeared to be largely driven by satisfaction with other agonists and a low prevalence of community knowledge about buprenorphine/naloxone.
Authors: Keith Ahamad; Kanna Hayashi; Paul Nguyen; Sabina Dobrer; Thomas Kerr; Christian G Schütz; Julio S Montaner; Evan Wood Journal: Lancet HIV Date: 2015-08-06 Impact factor: 12.767
Authors: Susan G Sherman; Catherine Sutcliffe; Bangorn Srirojn; Carl A Latkin; Apinun Aramratanna; David D Celentano Journal: Soc Sci Med Date: 2008-11-03 Impact factor: 4.634
Authors: Bobbi Jo H Yarborough; Scott P Stumbo; Dennis McCarty; Jennifer Mertens; Constance Weisner; Carla A Green Journal: Drug Alcohol Depend Date: 2016-01-06 Impact factor: 4.492
Authors: Robert Hämmig; Antje Kemter; Johannes Strasser; Ulrich von Bardeleben; Barbara Gugger; Marc Walter; Kenneth M Dürsteler; Marc Vogel Journal: Subst Abuse Rehabil Date: 2016-07-20
Authors: Derjung M Tarn; Kevin J Shih; Allison J Ober; Sarah B Hunter; Katherine E Watkins; Jeremy Martinez; Alanna Montero; Michael McCreary; Isabel Leamon; John Sheehe; Elizabeth Bromley Journal: Community Ment Health J Date: 2022-07-29
Authors: Tara Gomes; Daniel McCormack; Nikki Bozinoff; Mina Tadrous; Tony Antoniou; Charlotte Munro; Tonya Campbell; J Michael Paterson; Muhammad Mamdani; Beth Sproule Journal: Addiction Date: 2022-03-21 Impact factor: 7.256